Hint­ing at an IPO and big things ahead for syn­thet­ic lethal­i­ty, pre­clin­i­cal Ideaya touts a $94M round

Big botech ven­ture rounds are com­ing fast and fu­ri­ous in Q1, and much of the mon­ey is be­ing fun­neled in­to pre­clin­i­cal out­fits like Ideaya Bio­sciences — abun­dant­ly hope­ful on promise in a hot can­cer R&D field but skimpy with de­tails.

The South San Fran­cis­co-based biotech has all the key fea­tures that’s made biotech such a trendy in­vest­ment for packed syn­di­cates. And to­day it’s tak­ing the wraps off a whop­ping $94 mil­lion B round.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER